Sector
PharmaceuticalsOpen
₹17.9Prev. Close
₹18.2Turnover(Lac.)
₹0.17Day's High
₹17.9Day's Low
₹17.3552 Week's High
₹4652 Week's Low
₹17.71Book Value
₹18.29Face Value
₹10Mkt Cap (₹ Cr.)
8.87P/E
113.75EPS
0.16Divi. Yield
031 Jan 2025
12:00 AM
Board Meeting
Agenda : Audited Result
9 Sep 2024
12:00 AM
BookCloser
9 Sep 2024
12:00 AM
AGM
Announcement Date: 09 Sep, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3.83 | 2.97 | 2.2 | 2.84 |
Net Worth | 8.92 | 8.06 | 7.29 | 7.93 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 14.07 | 12.81 | 15.14 | 10.93 |
yoy growth (%) | 9.84 | -15.37 | 38.5 | -16.6 |
Raw materials | -7.41 | -6.6 | -9.27 | -6.49 |
As % of sales | 52.7 | 51.56 | 61.24 | 59.41 |
Employee costs | -1.17 | -0.96 | -0.77 | -1 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -0.1 | 0.15 | 1.27 | -0.37 |
Depreciation | -1.27 | -0.65 | -0.32 | -0.37 |
Tax paid | -0.1 | -0.1 | -0.28 | -0.07 |
Working capital | 1.26 | -0.7 | 0.27 | -0.17 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 9.84 | -15.37 | 38.5 | -16.6 |
Op profit growth | 59.97 | -13.01 | -1,703.87 | -112.59 |
EBIT growth | -24.45 | -65.93 | -920.72 | -135.96 |
Net profit growth | 399.81 | -95.17 | -322.01 | -368.51 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.85 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,001.1 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,478.5 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,137.55 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,413.35 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Sanjay Sethi
Chairman & Non Executive Dir.
Sudhir Sethi
Independent Non Exe. Director
Abhinav Naik
Independent Non Exe. Director
Shreya Saraf
Company Sec. & Compli. Officer
Neha Sharma
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Beryl Drugs Ltd
Summary
Beryl Drugs Limited, based in Indore, was incorporated on August 24, 1993. The Company acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993. The Shares of Company were listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.The Company thereafter has been engaged in the manufacture, sale, and export of branded, generic pharmaceutical formulations in India and internationally. It offers I.V.fluids, and a range of small and large volume injectables. It provides a range of eye/ear drops, veterinary products, and injections. It sells products through sales and distribution network. In addition, it offers research and development, as well as contract manufacturing services. Beryl Drugs Ltd. is based in Indore, India.Beryl emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products. It owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.The manufacturing facilities of the Company are in compliance with WHO GMP specifications. The Company is in tune with the current manufacturing trends in healthcare industry. The Company is an ISO 9001:2000 certified for quality management, which acknowledges quality as the first and the foremost important aspect into the business of healthcare products.
Read More
What is the Beryl Drugs Ltd share price today?
The Beryl Drugs Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹17.48 today.
What is the Market Cap of Beryl Drugs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Beryl Drugs Ltd is ₹8.87 Cr. as of 09 May ‘25
What is the PE and PB ratio of Beryl Drugs Ltd?
The PE and PB ratios of Beryl Drugs Ltd is 113.75 and 0.99 as of 09 May ‘25
What is the 52 Week High and Low of Beryl Drugs Ltd?
The 52-week high/low is the highest and lowest price at which a Beryl Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Beryl Drugs Ltd is ₹17.71 and ₹46 as of 09 May ‘25
What is the CAGR of Beryl Drugs Ltd?
Beryl Drugs Ltd's CAGR for 5 Years at 38.82%, 3 Years at 25.04%, 1 Year at -46.52%, 6 Month at -54.23%, 3 Month at -43.36% and 1 Month at -20.87%.
What is the shareholding pattern of Beryl Drugs Ltd?
The shareholding pattern of Beryl Drugs Ltd is as follows:
Promoters - 26.38 %
Institutions - 0.00 %
Public - 73.62 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
